About Pro Medicus Limited (PME)
Pro Medicus Limited is a Health Information Services company operating in the Healthcare sector. The company is headquartered in Richmond, Australia. PME has been publicly traded since 2000, giving it 26+ years of trading history.
Pro Medicus Limited (PME) has been publicly traded since 2000, making it a 26-year-old public company. It operates in the Health Information Services industry within the Healthcare sector. The company is headquartered in Richmond, Australia and employs approximately 132 people. With a market capitalization of A$14 billion, PME is a large established company.
PME trades on the Australian Securities Exchange and is classified as a large-cap-cap stock with a market capitalization of approximately A$14 billion. The company employs approximately 132 people worldwide.
Key Statistics
- Current Price
- A$133.00
- Market Cap
- A$13.89B
- 52-Week High
- A$336.00
- 52-Week Low
- A$107.75
- Sector
- Healthcare
- Industry
- Health Information Services
PME Investment Performance
PME has declined 39.6% year-to-date in 2026. Over the past 5 years, a A$1,000 investment in PME would have grown to A$3,278, representing a 227.8% total return. Since its IPO in 2000, a A$1,000 investment would now be worth A$185,788.
A$1,000 Invested in Pro Medicus Limited (PME)
How much would A$1,000 invested in PME be worth today?
What would A$1,000 invested in PME 1 year ago be worth today?
A A$1,000 investment in Pro Medicus Limited (PME) in 2025 would be worth A$668 as of March 2026, representing a -33.2% total return.
What would A$1,000 invested in PME 3 years ago be worth today?
A A$1,000 investment in Pro Medicus Limited (PME) in 2023 would be worth A$2,105 as of March 2026, representing a +110.5% total return.
What would A$1,000 invested in PME 5 years ago be worth today?
A A$1,000 investment in Pro Medicus Limited (PME) in 2021 would be worth A$3,278 as of March 2026, representing a +227.8% total return.
What would A$1,000 invested in PME 10 years ago be worth today?
A A$1,000 investment in Pro Medicus Limited (PME) in 2016 would be worth A$41,018 as of March 2026, representing a +4001.8% total return.
What would A$1,000 invested in PME at IPO be worth today?
A A$1,000 investment in Pro Medicus Limited (PME) at IPO would be worth A$185,788 as of March 2026, representing a +18478.8% total return.
Monthly Returns Heatmap
Over the past 25+ years (305 months), Pro Medicus Limited (PME) has averaged a monthly return of +2.53% with a median return of +1.15%. The stock had 167 positive months (55%) and 132 negative months (43%). The best month in PME's history was July 2011 with a +45.7% return, while the worst was February 2026 at -29.2%. Historically, July tends to be the strongest month (averaging +7.6%), and February the weakest (-3.1%).
PME's longest winning streak was 10 consecutive months of gains, while its longest losing streak was 4 consecutive months of losses. The best full year was 2015 with a cumulative return of +126.9%, and the worst was 2011 at -47.7%.
Annual Returns
Over 26 years of trading history, Pro Medicus Limited (PME) has delivered an average annual return of +34.51% with a median return of +23.17%. The compound annual growth rate (CAGR) is +21.62%. The stock posted gains in 15 years (58%) and losses in 11 years (42%).
PME's best year was 2015 with a +210.88% gain, while the worst was 2011 at -50.88%. The longest streak of consecutive positive years was 10, and the longest losing streak was 4 years. PME achieved double-digit gains (10%+) in 15 years. It suffered double-digit losses in 9 years.
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | -39.62% | A$220.26 | A$133.00 |
| 2025 | -11.52% | A$248.95 | A$220.26 |
| 2024 | +161.84% | A$95.08 | A$248.95 |
| 2023 | +74.19% | A$54.58 | A$95.08 |
| 2022 | -11.11% | A$61.40 | A$54.58 |
| 2021 | +83.31% | A$33.50 | A$61.40 |
| 2020 | +53.66% | A$21.80 | A$33.50 |
| 2019 | +106.53% | A$10.55 | A$21.80 |
| 2018 | +25.55% | A$8.41 | A$10.55 |
| 2017 | +83.18% | A$4.59 | A$8.41 |
| 2016 | +44.36% | A$3.18 | A$4.59 |
| 2015 | +210.88% | A$1.02 | A$3.18 |
| 2014 | +59.40% | A$0.64 | A$1.02 |
| 2013 | +75.53% | A$0.37 | A$0.64 |
| 2012 | +55.09% | A$0.24 | A$0.37 |
| 2011 | -50.88% | A$0.48 | A$0.24 |
| 2010 | -35.51% | A$0.74 | A$0.48 |
| 2009 | -2.66% | A$0.76 | A$0.74 |
| 2008 | -26.60% | A$1.04 | A$0.76 |
| 2007 | +11.46% | A$0.93 | A$1.04 |
| 2006 | -7.77% | A$1.01 | A$0.93 |
| 2005 | +20.79% | A$0.84 | A$1.01 |
| 2004 | +57.82% | A$0.53 | A$0.84 |
| 2003 | -14.77% | A$0.62 | A$0.53 |
| 2002 | -15.35% | A$0.74 | A$0.62 |
| 2001 | -10.62% | A$0.82 | A$0.74 |
PME Investment Analysis: Valuation, Risk & Dividends
Key factors to consider when evaluating Pro Medicus Limited as an investment
Valuation
PME currently trades at a trailing P/E ratio of 59.1, which is considered high relative to the broader market. The forward P/E of 69.8 suggests analysts expect earnings to be higher in the coming year. The price-to-book ratio stands at 35.7. The price-to-sales ratio is 57.8.
Dividends
Pro Medicus Limited pays a dividend to shareholders with a current yield of 0.48%. This translates to A$0.64 per share annually. The payout ratio of 25% indicates sustainable dividend coverage.
Risk & Volatility
PME has a beta of 0.49, indicating it is less volatile than the overall market. The stock's 52-week range is A$107.75 to A$336.00, and it currently trades near its 52-week low.
Analyst Ratings
Based on 14 analyst opinions, PME has a consensus "buy" rating. The average price target of A$207.76 suggests 56.2% upside from current levels.
Frequently Asked Questions: PME
What sector is PME in? ▼
PME operates in the Healthcare sector, specifically in the Health Information Services industry. This sector includes pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare providers.
How has PME performed historically? ▼
Over 26 years of trading history, PME has posted gains in 15 years (58% of the time). The best year was 2015 with a +210.9% return. Past performance does not guarantee future results.
How can I invest in PME? ▼
You can invest in PME through any brokerage account that offers access to the Australian Securities Exchange. Popular options include commission-free brokers like Fidelity, Charles Schwab, or Robinhood (US), or international brokers like Interactive Brokers. You can buy individual shares or invest through ETFs that hold PME.
Does PME pay dividends? ▼
Pro Medicus Limited pays a dividend to shareholders with a current yield of 0.48%. This translates to A$0.64 per share annually. The payout ratio of 25% indicates sustainable dividend coverage.
What does Pro Medicus Limited do? ▼
Pro Medicus Limited is a Health Information Services company operating in the Healthcare sector. The company is headquartered in Richmond, Australia.
What sector is PME in? ▼
PME operates in the Healthcare sector, specifically in the Health Information Services industry.
When did PME go public? ▼
Pro Medicus Limited went public in 2000, making it a 26-year-old public company as of 2026.
How much would A$1,000 invested in PME 5 years ago be worth today? ▼
A A$1,000 investment in PME five years ago would be worth approximately A$3,278 today, representing a 227.8% return.
How much would A$1,000 invested in PME 10 years ago be worth today? ▼
A A$1,000 investment in PME ten years ago would be worth approximately A$41,018 today, representing a 4001.8% total return over the decade.
What is PME's 3-year return? ▼
Over the past 3 years, PME has returned 110.5%. A A$1,000 investment would have grown to A$2,105.
How much would A$1,000 invested in PME at IPO be worth today? ▼
If you invested A$1,000 in PME at its IPO in 2000, it would be worth approximately A$185,788 today, a 18,478.8% return over 26 years.
Does PME pay dividends? ▼
Yes, Pro Medicus Limited pays a dividend with a current yield of 0.48%, which is A$0.64 per share annually.
What is PME's market cap? ▼
Pro Medicus Limited has a market capitalization of A$14 billion, classifying it as a large-cap company.
What is PME's P/E ratio? ▼
PME has a trailing P/E ratio of 59.1 and a forward P/E of 69.8, which measures how much investors are paying per dollar of earnings.
Is PME a buy, hold, or sell? ▼
Based on 14 opinions, PME has a consensus "buy" rating. The average price target is A$207.76.
Last updated: 3/15/2026